Journal Articles

Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa inhibitor Abciximab for Saphenous Vein Graft Interventions

October 30, 2015

Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa inhibitor Abciximab for Saphenous Vein Graft Interventions, 30 oct, 2015, Cardiovascular Revascularization Medicine, Ralf E. HarskampNiels Hoedemaker, L. Kristin Newby, Pier Woudstra, Maik J. Grundeken, Marcel A. Beijk, Jan J. Piek, Jan G. Tijssen, Rajendra H. Mehta, Robbert J. de Winter

  • Academic Medical Center – University of Amsterdam, Amsterdam, The Netherlands,VU University Medical Center, Amsterdam, The Netherlands, Duke Clinical Research Institute, Durham, NC, USA

Abstract

Background

Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) poses a high-risk for distal coronary thromboembolic events. Glycoprotein IIb/IIIa inhibitors are frequently used in hope of reducing the impact of this, although the safety and efficacy of these drugs to improve outcomes in this setting are understudied.

Methods

Patients were included if they had prior coronary artery bypass surgery and subsequently underwent PCI of ≥1 SVG graft at a Dutch academic center between 1997–2008. These patients were matched 1:1 based on peri-procedural use of abciximab using a propensity-score matching algorithm based on 17 variables. Conditional logistic regression and Cox regression stratified on matched pairs were performed to evaluate the association between abciximab use and MACCE (the composite measure of mortality, myocardial infarction, stroke and repeat revascularization) at 30 days and up to 1 year.

Results

The composite of 30-day MACCE occurred in 18 patients (15.3%) in the abciximab group and 16 patients (13.6%) in the propensity matched control group (OR: 1.13, 95%-CI:0.57-2.21, p=0.73). At 1-year follow-up, MACCE rates were also similar (32.5% vs. 33.9%, HR: 0.97, 95%-CI:0.59-1.59). Major bleeding (BARC types 3a-c) was higher in the abciximab group (11.9% vs. 4.2%, OR: 2.80, 95%-CI:1.01-7.77). Ischemic outcomes did not differ among patients with acute coronary syndromes.

Conclusion

The use of intravenous abciximab was not associated with improved clinical outcomes up to 1-year among patients undergoing SVG PCI, but was related with more bleeding.

 

Comments are closed.

Connect With Us